Controlled release pde10a formulations

HK40137337APending Publication Date: 2026-09-11MERCK SHARP & DOHME LLC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026123962
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-29
Filing Date
2026-05-26
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to treatment of central nervous system disorders associated with phosphodiesterase 10A (PDE10A) such as schizophrenia, bipolar disease, and Alzheimer's disease, as therapeutics for neurological and psychiatric disorders. This disclosure provides controlled-release formulations of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine (Compound A) and their use in the treatment of schizophrenia and other psychiatric disorders that improves the tolerability profile.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This disclosure generally relates to the treatment of central nervous system disorders associated with phosphodiesterase 10A (PDE10A), including schizophrenia, bipolar disorder, and Alzheimer's disease, and can be used as a therapeutic agent for neurological and psychiatric disorders. This disclosure provides controlled-release formulations of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidine-4-amine (compound A), and the use of such formulations in the treatment of schizophrenia and other psychiatric disorders, with improved drug tolerability characteristics.

Claims

CLAIMSWhat is claimed is:

1. A controlled-release tablet formulation comprising a:1) first layer having about 1 %-25% by weight of pharmaceutically acceptable Compound A, represented by structural formula I:or a pharmaceutically acceptable salt, ester derivative, geometric isomer, stereoisomer, or optical isomer thereof and about 60-90% by weight low viscosity polyethylene oxide (PEG) polymer;2) second layer comprising about 50%-70% by weight high viscosity polyethylene oxide polymer, about 10%-40% by weight metal halide and about 5%-30% by weight tableting agent; and3) semipermeable coating wherein the coating comprises about 1 %- 15% by weight of the tablet, said tablet having an orifice in the first layer.

2. The formulation according to claim 1 wherein the low viscosity polyethylene oxide has a molecular weight range (g / mol) of about 100, 000 to 300,000 and is present in the first layer at about 65%-88% by weight.

3. The formulation according to any of claims 1 to 2 wherein the high viscosity polyethylene oxide has a molecular weight range (g / mol) of about 4,000,000 to 7,000,000 and is present in the second layer at about 50%-70% by weight.

4. The formulation according to any one of claims 1 to 3 wherein the tableting agent is selected from lactose, spray dried lactose, microcrystalline cellulose, mannitol, sorbitol, dibasic calcium phosphate dehydrate, and calcium sulphate dehydrate.

5. The formulation according to claim 4 wherein the tableting agent is microcry stalline cellulose, present at about 10%-20% by weight.

6. The formulation according to any of claims 1 to 5 wherein the metal halide selected from sodium chloride, potassium chloride, calcium chloride, potassium iodide, mixture thereof, and is present at about 15%-25% by weight.

7. The formulation according to any of claims 1 to 6 wherein the semipermeable coating comprises cellulose acetate, ethyl cellulose, or a combination thereof and low molecular weight polyethylene glycol.

8. The formulation according to any of claims 1 to 7 wherein Compound A, or a pharmaceutically acceptable salt, ester derivative, geometric isomer, stereoisomer, or optical isomer thereof is present at about 4%-25% by weight, and low viscosity polyethylene oxide has a molecular weight range (g / mol) of about 100,000 to 300,000 and is present at about 65%-88% by weight of total first layer weight.

9. The formulation according to any of claims 1 to 8 wherein, a) the high viscosity polyethylene oxide has a molecular weight range (g / mol) of about 4,000,000 to 7,000,000 and is present at about 60%-68% by weight, b)the tableting agent is present up tol0%-20% by weight, and c)the metal halide is present at about 15%-25% by weight of total weight of the second layer.

10. The formulation according to any of claims 1 to 9 wherein 5%-l 5% of the semipermeable coating comprises cellulose acetate, ethyl cellulose, or mixture thereof, wherein the cellulose acetate, ethyl cellulose, or mixture thereof contains about 5%-20%, by weight, of low molecular weight polyethylene glycol.

11. The formulation according to any of claims 1 to 10 wherein a sugar alcohol selected from mannitol, sucrose, and lactose is optionally present.

12. The formulation according to any of claims 1 to 11 that exhibits peak to trough concentration levels of Compound A from about 1.0 to about 3.5.

13. The formulation according to any of claims 1 to 12 comprising from about 17 mg to about 47 mg of Compound A which can be administered once daily with no incidence of dystonia.

14. The formulation according to any of claims 1 to 13 comprising Compound A at doses at 16mg or higher which exhibits sustained muscarinic enzyme occupancy at both peak and trough of about 65% or higher.

15. The formulation according to any of claims 1 to 14, comprising about 17mg to about 47mg Compound A.

16. The formulation according to claim 15, wherein when administered in a patient population suffering from schizophrenia there are no reported incidents of dystonia.

17. A method for treating schizophrenia or other psychiatric disorders in a patient in need thereof, comprising administering to the patient a controlled-release formulation of Compound A according to any of Claims 1 to 16 at doses of 16mg or higher without inducing dystonia in the patient.

18. The method according to claim 17 wherein Compound A is administered to the patient at a dose of about 17mg to about 47mg without inducing dystonia in the patient.